Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) Free Cash Flow (FCF): $1.15B

The free cash flow (FCF) for Agilent Technologies, Inc. (A) is $1.15B. It is below its 12-month average by 8.75% ($1.26B).

A Free Cash Flow (FCF) Chart

A Free Cash Flow (FCF)
$1.15B-16.10% 1Y
Zoom

A Average Free Cash Flow (FCF) Chart

A Current vs Average Free Cash Flow (FCF) Chart

A Free Cash Flow (FCF) Metrics

FREE CASH FLOW (FCF)

$1.15B

FREE CASH FLOW (FCF) AVG TTM

$1.26B

FREE CASH FLOW (FCF) AVG 3Y

$1.25B

FREE CASH FLOW (FCF) AVG 5Y

$1.19B

FREE CASH FLOW (FCF) AVG 10Y

$968.45M

FREE CASH FLOW (FCF) AVG 15Y

$926.00M

FREE CASH FLOW (FCF) AVG 20Y

$843.90M

CURRENT VS TTM AVG

-8.75%

CURRENT VS 3Y AVG

-8.21%

CURRENT VS 5Y AVG

-2.89%

CURRENT VS 10Y AVG

+18.95%

CURRENT VS 15Y AVG

+24.41%

CURRENT VS 20Y AVG

+36.51%

FCF Analysis

Free Cash Flow (TTM)

$1.15B

FCF Yield

3.26%

Price/FCF

30.6

Formula: FCF = Operating Cash Flow - Capital Expenditures

Why FCF matters:

  • Shows actual cash available (not accounting earnings)
  • Funds dividends, buybacks, and debt reduction
  • Less susceptible to accounting manipulation than net income
  • Key metric for DCF valuation models

Agilent Technologies, Inc. Free Cash Flow (FCF) Formula & Definition

Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Agilent Technologies, Inc. Free Cash Flow (FCF) FAQ

What is the free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The free cash flow (FCF) for A stock is $1.15B.
What is the TTM average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The TTM average free cash flow (FCF) for A stock is $1.26B.
What is the 3Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The 3Y average free cash flow (FCF) for A stock is $1.25B.
What is the 5Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The 5Y average free cash flow (FCF) for A stock is $1.19B.
What is the 10Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The 10Y average free cash flow (FCF) for A stock is $968.45M.
What is the 15Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The 15Y average free cash flow (FCF) for A stock is $926.00M.
What is the 20Y average free cash flow (FCF) for Agilent Technologies, Inc. (A)?
The 20Y average free cash flow (FCF) for A stock is $843.90M.

Agilent Technologies, Inc. Free Cash Flow (FCF) History

DATEFREE CASH FLOW (FCF)
2025-10-31$1.15B
2024-10-31$1.37B
2023-10-31$1.47B
2022-10-31$1.02B
2021-10-31$1.30B
2020-10-31$802.00M
2019-10-31$865.00M
2018-10-31$910.00M
2017-10-31$713.00M
2016-10-31$654.00M
2015-10-31$393.00M
2014-10-31$506.00M
2013-10-31$957.00M
2012-10-31$1.03B
2011-10-31$1.07B
2010-10-31$593.00M
2009-10-31$280.00M
2008-10-31$602.00M
2007-10-31$815.00M
2006-10-31$449.00M
2005-10-31$760.00M
2004-10-31$586.00M
2003-10-31$-349.00M
2002-10-31$-799.00M
2001-10-31$621.00M
2000-10-31$14.00M
1999-10-31$27.00M
1998-10-31$341.00M

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell